VCEL
Vericel Corp Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$40.26Close
$2.0BMarket cap
$29.34 – $48.3152-week range
Nov 5, 2026Next report · before the open
Highlights
Cautions
- Trend not confirmed 6 of 8 conditions · under the 50-day, RS under 70
- Lagging the market RS 49 · weaker than 51% of stocks over 12 months
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
17%
1wk
down 5.3%
price change
1mo
up 0.3%
price change
12-month return
up 17%
market up 11% ·
its own up 5%
F-score
7 / 9
Strong
Altman Z
9.22
Low risk
P/E
123.4×
price / earnings
PEG
2.13
P/E / EPS growth
P/B
5.7×
price / book
Earnings yield
up 0.6%
EBIT / enterprise value
Cheaper than
29%
of the market · expensive
Revenue growth
up 16%
year on year
EPS growth
—
latest quarter
Sales growth
up 22%
latest quarter · -8 pts
ROE
up 5%
return on equity
Free cash margin
up 9%
$24.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-4.4×
net cash
Interest cover
—EBIT / interest
Piotroski tests
- issued more shares
- assets working less efficiently
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
- gross margin widened
Repair signals
- FCF turned positive ($-6M → $25M)
- Gross margin 72.6% → 74.4%
Trade setup
ATR%
4.0%
$1.62 a day · 2×ATR $37.02
RS
49 / 99
vs the universe
Trend
6 / 8
under the 50-day, RS under 70
Relative volume
1.1×
vs 50-day average
Up/down volume
1.07
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 6 of 8
- Price above the 50-day average: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Jul 30, 2026
Financials
- Gross 74%
- Net 6%
- Free cash 9%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $122.0M | $153.1M | $163.7M | $197.5M | $237.2M | $276.3M |
| Gross margin | 69% | 69% | 67% | 69% | 73% | 74% |
| Operating income | $2.4M | -$7.9M | -$17.1M | -$6.5M | $4.5M | $11.0M |
| Net income | $2.9M | -$7.5M | -$16.7M | -$3.2M | $10.4M | $16.5M |
| Net margin | 2% | -5% | -10% | -2% | 4% | 6% |
| Earnings per share | $0.06 | -$0.16 | -$0.35 | -$0.07 | $0.20 | $0.32 |
| Free cash flow | $14.9M | $21.1M | $10.1M | $15.3M | -$5.8M | $24.7M |
| Free cash margin | 12% | 14% | 6% | 8% | -2% | 9% |
| Cash | $33.6M | $68.3M | $51.1M | $69.1M | $74.5M | $100.1M |
| Shareholders' equity | $134.3M | $170.5M | $192.3M | $226.0M | $292.0M | $354.6M |
| Shares outstanding | 45.80m | 46.88m | 47.25m | 47.83m | 49.63m | 50.62m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Jul 30, 2026 | Quarterly ↗ | Jun 30, 2026 | 30d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Jul 31, 2025 | Quarterly ↗ | Jun 30, 2025 | 31d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Jul 30, 2026 | Results ↗ |
| May 18, 2026 | Charter or bylaws ↗ |
| May 7, 2026 | Results ↗ |
| May 1, 2026 | Shareholder vote ↗ |
| Feb 26, 2026 | Results ↗ |
| Jan 13, 2026 | Results · Regulation FD ↗ |
| Nov 6, 2025 | Results ↗ |
| Jul 31, 2025 | Results ↗ |
| May 8, 2025 | Results ↗ |
| May 2, 2025 | Director or officer change · Shareholder vote ↗ |
| Apr 14, 2025 | Regulation FD ↗ |
| Feb 27, 2025 | Results ↗ |